Choreo LLC Buys Shares of 20,895 Catalyst Pharmaceuticals, Inc. $CPRX

Choreo LLC purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 20,895 shares of the biopharmaceutical company’s stock, valued at approximately $412,000.

Other large investors also recently made changes to their positions in the company. Fox Run Management L.L.C. bought a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $258,000. Chase Investment Counsel Corp boosted its position in Catalyst Pharmaceuticals by 11.1% during the third quarter. Chase Investment Counsel Corp now owns 60,000 shares of the biopharmaceutical company’s stock worth $1,182,000 after purchasing an additional 6,000 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in Catalyst Pharmaceuticals during the third quarter valued at approximately $1,027,000. Persistent Asset Partners Ltd acquired a new position in Catalyst Pharmaceuticals during the third quarter valued at approximately $225,000. Finally, Rothschild Investment LLC raised its position in shares of Catalyst Pharmaceuticals by 1,085.7% in the third quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,520 shares during the period. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 0.3%

CPRX stock opened at $24.24 on Friday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $26.58. The company has a market cap of $2.96 billion, a PE ratio of 14.34, a price-to-earnings-growth ratio of 0.72 and a beta of 0.75. The business’s 50-day simple moving average is $23.85 and its 200 day simple moving average is $22.34.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several recent analyst reports. Oppenheimer reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Citigroup raised their price target on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Zacks Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $34.00.

Insider Activity

In other news, Director Molly Harper sold 26,746 shares of Catalyst Pharmaceuticals stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $23.25, for a total transaction of $621,844.50. Following the sale, the director directly owned 2,360 shares in the company, valued at approximately $54,870. The trade was a 91.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.40% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).